Deutsche Bank sets Neurocrine stock with $138 price target
Deutsche Bank (ETR:DBKGn) began coverage on Neurocrine Biosciences (NASDAQ:NBIX) stock, assigning a Hold rating and setting a price target of $138. The bank's analyst noted that with a current market ...
Neurocrine initiated with a Hold at Deutsche Bank
Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Maximize Your Portfolio with Data Driven ...
Analysts Are Bullish on These Healthcare Stocks: Labcorp Holdings (LH), Neurocrine (NBIX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Labcorp Holdings (LH – Research Report) and ...
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $163.00 at Guggenheim
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...
Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...
Mirae Asset Global Investments Co. Ltd. Grows Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 21.8% in the fourth quarter, according to the company in its most ...